Background: Experimental studies have demonstrated that 5-fluorouracil (5-FU) enhances zidovudine (AZT)-induced DNA strand breaks and cytotoxicity. Phase I studies have demonstrated that the maximum tolerable dose (MTD) of AZT is 8000 mg/sqm when administered i.v. over two hours after weekly 5-FU + 1-leucovorin (LV), and that this combination has promising antitumor activity. The purpose of this study was therefore to evaluate the antitumor activity of weekly bolus 5-FU + LV + AZT, administered at its MTD, and to determine whether 5-FU enhances AZT-induced DNA strand breaks in blood nuclear cells.
Introduction
Zidovudine (AZT) is a toxic thymidine analogue which was mainly developed as an antiretroviral agent and has shown significant activity in vitro against the human immunodeficency virus-1 (HIV-1) and clinical utility in patients with AIDS and AIDS-related diseases [1] [2] [3] . AZT is phosphorylated intracellularly by thymidine kinase (TK) and can be ultimately incorporated into DNA as AZT triphosphate (AZTTP) where it blocks chain elongation [2] . AZTTP is a more favourable substrate for HIV reverse transcriptase than for human DNA polymerase and is, therefore, more efficiently incorporated into viral than into cellular DNA, resulting in important anti-HIV activity and negligible cytotoxicity [1, 2, 4] . More recently, several experimental studies by our group as well as others have demonstrated that AZT incorporation into DNA, AZT-induced DNA strand breaks and AZT cytotoxicity in cancer cells can be markedly enhanced when AZT is combined with agents that inhibit de novo thymidylate (dTMP) synthesis, such as 5-fluorouracil (5-FU), methotrexate (MTX), hydroxyurea and ZD1694 [5] [6] [7] [8] [9] [10] [11] [12] . In fact, these agents, by depleting intracellular thymidine triphosphate (dTTP) pools, facilitate the utilisation of AZTTP in DNA synthesis [7, 8, 13] . We have also demonstrated that this effect is evident also in vivo in nude mice bearing xenografts of the human colorectal cancer cell line HCT-8 [7] . These studies also demonstrated that the enhancement of AZT incorporation into DNA was relatively specific for cancer cells and that this reflects biochemical differences between 'normal'and neoplastic cells with regard to thymidine salvage capacity and transport [7, [14] [15] [16] [17] [18] [19] [20] [21] , On the basis of these preclinical observations, we recently conducted a phase I study with intravenous AZT in combination with weekly 5-FU 500 mg/m 2 and the 1-isomer form of leucovorin (LV) 250 mg/m 2 in chemotherapy-naive metastatic colorectal cancer patients [22] . In this trial, in contrast to previous studies, a short intravenous infusion of AZT was used to reach peak plasma levels similar to those previously found to be effective in experimental murine models [7, 8] . Results demonstrated that AZT doses ^ 6 g/m 2 i.v. over 90-120 minutes were able to produce peak plasma concentrations (Cmax) and area under the concentration/time curve (AUC) values similar to those previously demonstrated to be effective in murine tumor models and that the maximum tolerable AZT dose (MTD) was 8 g/ m 2 ,with hypotension being its dose-limiting toxicity. Furthermore, this combination with 5-FU + LV + AZT demonstrated promising activity, with an objective response rate of 44% (95% confidence interval 27% to 62%) and with a trend toward an increased response rate with higher AZT doses.
The aim of the present phase II study was, therefore, to determine the activity of weekly 5-FU + LV + AZT with AZT given at its MTD of 8 g/m 2 in previously untreated metastatic colorectal cancer patients. Furthermore, a second objective was to elucidate the biological interaction between 5-FU and AZT in humans and, in particular, to investigate if the enhancement of AZTinduced DNA strand breaks by 5-FU, previously demonstrated in preclinical experimental models [5] , could be confirmed also clinically in peripheral nuclear blood cells of metastatic colorectal cancer patients.
Patients and methods

Drugs and chemicals
AZT (Retrovir) was generously provided by Glaxo-Wellcome (Beckenam, UK) in 200 mg vials. All chemicals were obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Patient selection
Different patients were accrued to determine the activity of 5-FU + LV + AZT or the effects on DNA of peripheral nuclear cells. In the phase II study, where the main purpose was to determine the activity of AZT at its MTD in combination with 5-FU + LV, the main elegibility criteria included: histologically confirmed diagnosis of colorectal adenocarcinoma with metastatic disease, Eastern Cooperative Oncology Group (ECOG) performace status <2, measurable disease, no previous adjuvant or palliative chemotherapy, leukocyte count 3500/mm 3 , platelet count > 100.000/mm 3 , serum creatinine =£1.5 mg/dl, serum bilirubin $1.5 mg/dl and transaminases $2.5 times normal values. Patients with a history of other malignant tumor (except in situ carcinoma of the cervix or non-melanoma skin cancer), symptomatic cardiac disease or recent history of myocardial infarction or arrhythmia, active infections or cerebral metastases were excluded. To determine the effects of 5-FU + LV, AZT and 5-FU + LV + AZTon DNA strand-breaks of peripheral mononuclear blood cells, the same selection criteria were used, but also patients with non-measurable or non-evaluable metastatic disease could be included in the study Approval for these studies was obtained from the local Ethical Committee; patients were informed of the nature of the study, gave their informed consent and were pre-registered before entry into the study.
Treatment and study design
In the phase II study, 5-FU was administered as i.v. bolus (3-5 minutes) at a dose of 500 mg/m 2 in the middle of a 2-hour i.v. infusion of the 1 isomer form of leucovorin 250 mg/m 2 . AZT 8 g/m 2 was diluted in approximately 1.5 L of sodium chloride 0.9% and given i.v. over 120 minutes starting after the end of the LV infusion. Treatment was repeated every week at full doses if WBC > 2000 mm 3 , PLT Jt 75.000 mm 3 , there was no persistent diarrhea or stomatitis > grade 1 and if WHO grades II I-IV toxicities had not occurred. In instances of WBC <2000, PLT < 75.000 or persistent diarrhea or stomatitis > grade 1 treatment was delayed one week. If grade III non-haematological toxicity had occurred, treatment was continued, after recovery, with the 5-FU and AZT doses reduced by 20% (the LV dose was not modified). In the presence of grade 4 toxicity chemotherapy was definitively discontinued, or continued with the 5-FU and AZT doses reduced by 50%. Treatment was continued for a maximum of 26 weekly cycles or until the advent of progressive disease or intolerable toxic effects. If a further improvement was noticed after 26 cycles, treatment was continued for a total of 34 weekly cycles.
In the separate group of patients in whom DNA strand breaks were determined in peripheral nuclear blood cells, 5-FU 500 mg/m 2 , LV 250 mg/m 2 and AZT 8 g/m 2 were administered as in the phase II study, but patients received three separate weekly courses of 5-FU + LV without AZT or AZT alone or 5-FU + LV + AZT. The sequence of administration of the three different treatments was randomly determined on the hypothesis that a cumulative effect on DNA damage could be observed. After the three weeks of treatment with 5-FU + LV, AZT and 5-FU + LV + AZT patients were treated with 5-FU 370 mg/ m 2 + LV 100 mg/m 2 i.v. bolus for five consecutive days every 28 days for 6-8 months or until disease progression Assessability, toxicity and response criteria Pretreatment evaluation included history and physical examination, performance status assessment, complete blood cell with differential and platelet counts, complete blood profile, carcinocmbryonic antigen (CEA), urine analysis, electrocardiogram, chest X-ray or computed tomography (CT) scan, abdominal CTscan and/or sonogram and any other appropriate diagnostic procedure appropriate for evaluating metastatic sites. During treatment, a physical examination and complete blood cell count were repeated every week, blood profile, urine analysis and CEA every four weeks, and sites of metastatic disease were evaluated every eight weeks with radiographs or CTscan. A chest X-ray and/or an abdominal sonogram were repeated every six months if there was no evidence of lung or abdominal disease. Toxicity and responses were scored according to standard WHO criteria [23] In particular, complete response (CR) was defined as the complete disappearance of all known disease demonstrated at two separate examinations performed at least eight weeks apart; partial response (PR), a 50% or greater decrease in total tumor area demonstrated at two separate examinations performed at least eight weeks apart; minor response (MR), a 25%-50% decrease in total tumor area; stable disease (SD), when neither a < 25% decrease nor a < 25% increase in total tumor area had been demonstrated for at least eight weeks; progressive disease (PD), the appearance of any new lesion not previously identified or a > 25% increase of one or more existing lesions. Durations of response were calculated from the first day of treatment to the date of first observation of progressive disease or last examination.
Analysis of DNA strand breaks
Single strand breaks (SSB) in DNA from peripheral blood nucleated cells were measured before, and 24 and 48 hours after the start of treatment with AZTor 5-FU + LVor5-FU + LV + AZT. A fluorescent analysis of DNA unwinding, previously described and modified for whole blood cellular populations by collection in heparinized tubes and lysis of erythrocytes without further separation of cells, was used to evaluate the percentage of double-stranded and single-stranded DNA [24] . Briefly, blood samples (10 ml) from patients were collected in heparinized tubes and were mixed with 9 ml of solution A (0.87% NH 4 CI, 10 mM Tns-HCI (pH 7.2)) and held at 0°C for 20-30 min until lysis of erythrocytes was complete. The suspension was centrifuged (0 °C, 20 min, 400 g), the pellet suspended in 3 ml of solution A and cells were again centrifuged for 10 min. This pellet was suspended in 2 7 ml of solution B (0.25 M myo-inositol, 10 mM sodium phosphate, lmM MgCl 2 ) to give a total WBC concentration of 5-10 x 10 6 ml. Aliquots of this suspension (0.2 ml) were distributed into 12 disposable glass tubes designated T, P or B in groups of 4. T tubes were used to estimate the total fluorescence (double-stranded DNA + contaminants), P tubes to estimate the unwinding rate of DNA and B tubes (blank) to estimate the contribution to fluorescence by components other than double-stranded DNA. For this purpose, 0.2 ml of solution C (9 M urea, 10 mM NaOH, 2 5 mM cyclohexanediamine tetraacetate, and 0.1% sodium dodecylsulfate {SDS)) was added to each tube and incubated at 0°C for 10 min. After this time, during which cell lysis and chromatin disruption occurred, 0.1 ml of solution D (45% of solution B and 55% 0.2 N NaOH) and 0.1 ml of solution E (40% of solution C and 60% of 0.2 N NaOH) were gently added to the P and B tubes. After incubation at 0°C for a further 30 min during which the alkali diffused into the lysate to give a final pH of approximately 12.8, the contents of the B tubes were sonicated for 1-2 s to ensure rapid denaturation of the DNA in the alkaline solution; P and B tubes were further incubated at 15 °C for 60 min and then denaturation was stopped by chilling to 0°C and adding 0.4 ml of solution F (1 M glucose, and 14 mM p-mercaptoethanol) which lowered the pH to approximately 11.0 The lysates were briefly sonicated to render them homogeneous, diluted with 1.5 ml of solution G (ethidium bromide 6.7 ug/ml, and 13 3 mM NaOH) and their fluorescence was read at room temperature in a Perkin-Elmer spectrofluorometer (excitation wavelength 520 nm and emission 590 nm). The T tubes differed from the P tubes in that the neutralizing solution E was added before the alkaline C and D solutions so that the DNA was never exposed to a denaturing pH. The extent of DNA unwinding after a given time of exposure of cell extracts to alkali was calculated from the fluorescence values of the T, P and B samples. The percent of double stranded DNA is given by the formula (P-B)/(T-B) x 100 where (P-B) provides an estimate of the amount of double-stranded DNA remaining after exposure to alkali for 60 min, and (T-B) an estimate of the amount of double-stranded DNA in the cell extracts. Up to the point at which solution D was added, all steps were carried out under ordinary room illumination; after this, manipulations were carried out in the dark and incubations were in a covered bath. All solutions were kept at 0 °C except solutions C and G which were stored at room temperature
Statistical analysis
In the phase II trial, the optimal two-stage sequential sampling design described by Simon [25] was used to determine the number of patients to be included. Because responses with 5-FU bolus alone are observed in 10%-ll% of patients and with 5-FU bolus modulated by LV or MTX in approximately !9%-23% of patients [26, 27] , a response rate of 30% or greater with a 5-FU bolus-based regimen should be considered promising. Therefore, the design parameters pO (response rate in null hypothesis), and pi (response rate in alternative hypothesis) selected were 0.10 and 0.30, respectively. Considering also an error probability a of 0.05 and p of 0.20, the first stage of the study required 10 patients and, if at least one objective response was observed, the second stage required a total of 29 patients. If at least five patients responded after the second accrual stage the treatment was considered promising unless other considerations indicated otherwise.
The interaction between 5-FU + LV and AZT on DNA-induced single strand breaks of peripheral nuclear blood cells was analysed using a multiplicative model, as previously described [28, 29] . Briefly, the multiplication of the fraction of double stranded DNA remaining 
Results
Phase II study
From September 1994 to December 1995, 29 patients entered into this clinical trial. As shown in Table 1 where the patient characteristics are summarized, the median ECOG PS was 0 (range 0-1), the predominant site of metastasis was the liver and 11 patients had multiple metastatic sites. A total of 585 weekly cycles of 5-FU + LV + AZT were administered with a median of 20 cycles per patient (range 4-34). All patients are evaluable for toxicity, which consisted of diarrhea, stomatitis, nausea and vomiting, leukopenia, dermatitis, conjunctivitis and hypotension. As shown in Table 2 , toxicities were usually mild or moderate (WHO grade 1-2); grades III-IV toxicities, consisting of diarrhea (17%), nausea and vomiting (7%), stomatitis (3%), fever (3%) and leukopenia (3%). were uncommon. One patient, who had suffered an episode of myocardial infarction four years before study entry, died of a cardiac arrhytmia which occurred five days after the fourth weekly cycle as a consequence of grade IV diarrhea associated with hypokalemia. Nineteen patients required treatment delays (^ 1 week) or 5-FU and AZT dose reductions because of toxicity, with the median 5-FU and AZT dose intensities being, respectively, 442 mg/m 2 /week (range 280-500) and 6880 mg/m 2 /week (range 4480-8000). According to the intent to treat analysis, all entered patients were included for evaluation of response. Two additional patients, in whom disease was not actually reevaluated, were considered treatment failures (Table 3) ; one of these was the patient who died of toxicity after the fourth cycle and the other was one who was lost to follow-up after the fifth cycle and died, presumably of disease progression, four months after treatment start. Overall 3 (10%) complete and 10 (35%) partial responses were observed, for an objective response rate of 45% (95% confidence limit interval 26%-64%). Significant subjective improvement was observed in four of nine patients who initially had disease-related symptoms. The median time to response was two months (range 2 to 4) and the median duration of response eight months (range 2 to 17). Responses occurred in liver (10), lung (3), spleen (1) and retroperitoneum (1) . Of the remaining patients 6 (20%) had minor responses, 5 (17%) stable disease and 5 (17%) were treatment failures (three had documented disease progression) ( Table 3 ). The median time to progression and median survival times were 7.5 and 14 months, respectively.
Analysis ofDNA strand breaks in peripheral nuclear blood cells
Because previous studies have suggested that 5-FU enhances AZT cytotoxicity by increasing AZT incorporation into DNA and therefore by increasing AZTinduced DNA single-strand breaks [5, 7, 13] , 10 patients were studied for the frequency of DNA single-strand breaks in peripheral nuclear blood cells 24 and 48 hours after treatment with AZT 8 g/m 2 , 5-FU 500 mg/m 2 + LV 250 mg/m 2 and 5-FU + LV + AZT. All patients had metastatic colorectal cancer (six non-evaluable metastatic disease) and were chemotherapy-naive. Other characteristics included median age of 61 years, median ECOG PS of 0, nine were males and the most frequent metastatic sites were peritoneum and liver. Treatments were administered in three separate weeks in different sequences that were randomly determined. Results indicate that after treatment with AZT the mean values of double-stranded DNA decreased from approximately 93% to 70% and 59% after 24 and 48 hours, respectively. Similar effects on DNA were observed after treatment with 5-FU + LV, but the greatest effect was observed after treatment with 5-FU + LV + AZT which reduced the percentage of double stranded DNA to 50% and 36% after 24 and 48 hours, respectively (Figure 1 ). Seven days after treatment with AZT, 5-FU + LVand 5-FU + LV + AZT, no significant residual DNA damage was observed and the mean values of double-stranded DNA had returned to > 90%. The effect of combining 5-FU + LV with AZT on DNA was analysed using the multiplicative model previously described, and it was found to be additive. Of the four patients with evaluable disease one obtained a partial response.
Discussion
Despite the increased accumulation in recent decades of knowledge about the biology and treatment of cancer, the prognosis of metastatic colorectal cancer patients with unresectable disease remains very poor, with a median survival of only 10-12 months, and with fewer than 10% of its victims surviving longer than 36 months [26, 27, 30] . 5-FU has been in use for more than 30 years and is still the drug most often administered. However, 5-FU alone, given as an i.v. bolus, induces responses in only 10%-ll% of patients [26, 27] ; many attempts have been made to combine it with other agents or to modify the scheduling of its administration in an effort to biochemically modulate its cytotoxicity [31] . Although Recent experimental and clinical studies have suggested that a new approach to improving the treatment of colorectal cancer might be to combine a toxic thymidine analogue, such as AZT, with an inhibitor of dTMP synthesis such as 5-FU, MTX, tomudex and others [5] [6] [7] [8] [9] [10] [11] [12] . Indeed, these agents facilitate the incorporation of AZTTP into DNA by lowering intracellular dTTP pools and thus enhancing DNA damage and cytotoxicity [7, 8, 13] . Interestingly, experimental studies have demonstrated that this effect is more evident in colorectal cancer cells because of an elevated thymidine kinase activity (which activates AZT to AZTTP) and the lack of an efficient concentrative nucleoside transport for thymidine, since thymidine competes with AZT for phosphorylation and incorporation into DNA [7, [14] [15] [16] [17] [18] [19] [20] [21] . In initial phase I studies [42, 43] AZT, in combination with 5-FU and LV, was administered orally or in protracted (48 hours) intravenous infusions that did not render possible attainment of plasma AZT concentrations that had been demonstrated to be effective in nude mice bearing tumour xenografts (0.5-1 mmol/L) [7, 8] . Subsequent phase I studies, therefore, have used shorter intravenous infusions of high doses of AZT which have allowed achievement of peak plasma concentrations similar to those previously obtained in preclinical animal models and rendered possible a promising activity in previously untreated metastatic colorectal cancer patients [22, 44, 45] . However, these studies did not demonstrate an activity for 5-FU + LV + AZT in heavily pretreated metastatic colorectal cancer patients resistant to 5-FU [42, 43, 45] . This is not surprising, not only because heavily pretreated patients with bulky disease and chemoresistant tumours very rarely respond to any further chemotherapy, but also because the mechanism of action of the 5-FU + AZT combination requires that 5-FU possess some degree of activity. Indeed, if thymidylate synthase (TS) is not inhibited and therefore dTTP pools are not lowered, AZT incorporation into DNA is negligible and does not lead to a detectable clinical activity [13] . Of interest is the fact that these phase I studies [42, 43] demonstrated a dose-dependent biologic effect of AZT manifested by an increase in DNA strand breaks in peripheral nuclear blood cells. However, the possible enhancement by 5-FU of AZT incorporation into DNA and therefore of AZT-induced DNA single strand breaks, was not investigated.
In the present study, we evaluated the activity of a combination of 5-FU bolus+LV with high doses of intravenous AZT, administered at its MTD as a short (120') intravenous infusion, in chemotherapy-naive metastatic colorectal cancer patients, and we also investigated whether the enhancement of AZT-induced DNA strand breaks by 5-FU, previously demonstrated in experimental models, could be confirmed clinically in peripheral nuclear blood cells. Leucovorin was added to 5-FU to enhance TS inhibition, and therefore the depletion of dTTP pools, and AZT was administered starting 60' after 5-FU to ensure that high AZT tumour concentrations were present when TS was inhibited [46] . Although the response rate observed in this trial has a wide 95% confidence limit interval (26%-64%), the antitumor activity of this new combination appears promising; in fact, it compares favourably with that of similar regimens with weekly bolus 5-FU plus LV without AZT (response rates 20%-25%) [26] , and it is in the same range as that of more demanding regimens in which 24-48-hour or protracted infusions of 5-FU or chronomodulated infusions of 5-FU plus oxaliplatin have been used [34] [35] [36] [37] . These results, therefore, confirm the elevated activity of 5-FU + LV + AZT already observed in the previous phase I studies in chemotherapy-naive patients [22, 45] . This study also demonstrates that the combination of 5-FU + LV with AZT increases the amount of DNA damage and this might reflect an increased incorporation of AZT into DNA; nevertheless, because 5-FU + LV alone also induced DNA strand breaks, other mechanisms could be involved. Interestingly, the effect of combining 5-FU + LV with AZT on DNA was only additive and not synergistic as previously observed in colorectal cancer cells in experimental models [5] . A possible explanation is that blood cells, despite having an elevated TK activity, also possess an active thymidine transport that could partially protect them from the cytotoxic effects of AZT due to the competition between thymidine and AZT, [7, 18, 19] . Therefore, it will be important to study the induction of DNA damage in cancer cells of colorectal cancer patients after treatment with 5-FU + LV and AZT to determine whether these effects on DNA are similar to those observed in blood cells or, as demonstrated in experimental models, are more pronounced and the interaction between 5-FU + LVand AZT is synergistic.
In conclusion, because of these and previous findings with 5-FU + LV + AZT in metastatic colorectal cancer, further studies are warranted. In particular, these results will require confirmation in randomized trials in which the effects of this new combination on survival will also be determined. Furthermore, because of recent experimental findings demonstrating that AZT might circumvent cisplatinum resistance and synergistically potentiate the cytotoxicity of cisplatinum + 5-FU [47] , and also that alfa-interferon enhances AZT cytotoxicity [48] , phase I-II studies clinically testing these observations should be performed. Some have already been initiated [49] [50] [51] . Most notably, a phase I study in 12 patients with metastatic gastrointestinal carcinomas demonstrates the feasibility of a combination with 5-FU + LV + AZT and cisplatin, and some activity also in chemotherapy-pretreated patients [51] ; furthermore, a phase II study in HTLV-1 associated adult T-cell leukemia-lymphoma with a combination of AZT and alfa-interferon demonstrates a significant activity for this combination, with eight of nine patients obtaining an objective response [49] . Finally, it will be of interest to combine AZT with 5-FU administered in continuous infusion because of its more specific effect on TS when compared with 5-FU bolus [52] ; similarly, it will be interesting to combine AZT with the new folate-based TS inhibitors such as tomudex which, being very specific and effective inhibitors of TS, might enhance AZT antitumor activity even more efficiently than 5-FU.
